These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22843292)

  • 21. Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells.
    Siders WM; Garron C; Shields J; Kaplan JM
    Clin Transl Sci; 2009 Feb; 2(1):75-9. PubMed ID: 20443871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
    Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
    Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.
    Boczkowski D; Nair SK; Nam JH; Lyerly HK; Gilboa E
    Cancer Res; 2000 Feb; 60(4):1028-34. PubMed ID: 10706120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
    Dell K; Klein C; Gissmann L
    Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA.
    Osman Y; Narita M; Ayres F; Takahashi M; Alldawi L; Tatsuo F; Toba K; Hirohashi T; Aizawa Y
    Cytotherapy; 2003; 5(2):161-8. PubMed ID: 12745578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
    You J; Wang CL; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT).
    Saebøe-Larssen S; Fossberg E; Gaudernack G
    J Immunol Methods; 2002 Jan; 259(1-2):191-203. PubMed ID: 11730854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigen-specific mRNA transfection of autologous dendritic cells.
    Benencia F
    Methods Mol Biol; 2014; 1139():77-86. PubMed ID: 24619672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma.
    Yu Z; Ma B; Zhou Y; Zhang M; Qiu X; Fan Q
    Exp Oncol; 2005 Dec; 27(4):273-8. PubMed ID: 16404346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells.
    Grünebach F; Erndt S; Häntschel M; Heine A; Brossart P
    Cancer Immunol Immunother; 2008 Oct; 57(10):1483-91. PubMed ID: 18301890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.
    Nair SK; Morse M; Boczkowski D; Cumming RI; Vasovic L; Gilboa E; Lyerly HK
    Ann Surg; 2002 Apr; 235(4):540-9. PubMed ID: 11923611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonlysosomal Route of mRNA Delivery and Combining with Epigenetic Regulation Optimized Antitumor Immunoprophylactic Efficacy.
    Liu Y; Liu X; Huang J; Shi Y; Luo Z; Zhang J; Guo X; Jiang M; Li X; Yin H; Qin B; Guan G; Luo L; Zhou Y; You J
    Adv Healthc Mater; 2023 Feb; 12(4):e2202460. PubMed ID: 36366890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
    Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
    Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.
    Kyte JA; Kvalheim G; Aamdal S; Saebøe-Larssen S; Gaudernack G
    Cancer Gene Ther; 2005 Jun; 12(6):579-91. PubMed ID: 15818380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell vaccine with mRNA targeted to the proteasome by polyubiquitination.
    Hosoi A; Takeda Y; Sakuta K; Ueha S; Kurachi M; Kimura K; Maekawa R; Kakimi K
    Biochem Biophys Res Commun; 2008 Jun; 371(2):242-6. PubMed ID: 18423376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
    Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
    Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.